

SURGICAL INNOVATION >> VALUE DRIVEN

SEP 3 0 2009

510(k) Summary

Submitter:

Parcus Medical, LLC

839 South Neenah Ave.

Sturgeon Bay, WI 54234

Company Contact:

Barton Bracy

Phone: (920) 746-2972 Fax: (920) 746-8665

Date Prepared:

April 13, 2009

Trade Name:

Parcus V-LoX<sup>™</sup> PEEK CF Suture Anchor

Common Name:

Suture Anchor

Classification Name: Fastener, Fixation, Non-Degradable, Soft Tissue 21 CFR 888 3040 - Product Code HWC and MBI

#### **Predicate Devices:**

Parcus V-LoX Titanium Suture Anchor (K090075)

Smith & Nephew TWINFIX FT PK (K072785)

#### **Device Description:**

The Parcus V-LoX PEEK CF Suture Anchor is a threaded, tapered fastener for use in attachment of soft tissue to bone. The device is made from Carbon Fiber Reinforced Polyetheretherketone (PEEK CF). It comes preloaded with two #2 sutures either with or without attached needles, and is available in two different diameters, 5.5mm and 6.5mm.

#### Intended Use:

The Parcus V-LoX<sup>TM</sup> PEEK CF Suture Anchors are indicated for attachment of soft tissue to bone. This product is intended for the following indications:

Shoulder.

Rotator Cuff Repair, Acromioclavicular Separation Repair, Bankart Lesion

Repair, Biceps Tenodesis, Capsular Shift or Capsulolabral Reconstruction, Deltoid Repair, SLAP Lesion Repair.

Knee

Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Posterior Oblique Ligament Repair, Extra Capsular Reconstruction,

Iliotibial Band Tenodesis, Patellar Ligament and Tendon Avulsion Repair.

Page 15 of 144



#### SURGICAL INNOVATION >> VALUE DRIVEN

Lateral Stabilization, Medial Stabilization, Midfoot Reconstruction, Achilles Foot/Ankle

Tendon Repair, Hallux Valgus Reconstruction, Metatarsal Ligament

Repair.

Tennis Elbow Repair, Biceps Tendon Reattachment. Elbow

Hand/Wrist Scapholunate Ligament Reconstruction, Ulnar or Radial Collateral

Ligament Reconstruction, TFCC.

#### Substantial Equivalence Summary:

The Parcus V-LoX PEEK CF Suture Anchors are essentially the same as the Parcus V-LoX Titanium Suture Anchors aside from the difference in material.

The only difference between the materials for the Parcus V-LoX PEEK CF Suture Anchor and the Smith & Nephew TWINFIX FT PK is that the Parcus Suture Anchor is carbon reinforced. Carbon fibers have been used clinically for more than 20 years as a reinforcement component for implant materials without obvious leachable-related biocompatibility reactions. Furthermore, there are currently several medical device implants on the market made from PEEK CF (e.g. Zimmer Spine BAK® Vista® Radiolucent Interbody Fusion System and the Depuy Spine OCELOT<sup>™</sup> Stackable Cage System).

Therefore the Parcus V-LoX PEEK CF Suture Anchor is substantially equivalent to the predicate devices listed above in which the basic features and intended uses are the same. Any differences between the V-LoX PEEK CF Suture Anchor and the predicate devices are considered minor and do not raise questions concerning safety and effectiveness.

### Summary Performance Data:

The Parcus V-LoX PEEK CF Suture Anchors were placed in prepared holes and the pull out strength and insertion torque was measured. Test results were compared to the results for the Parcus V-LoX Titanium Suture Anchors and demonstrated substantial equivalence.

# DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center – WO66-0609 Silver Spring, MD 20993-0002

SEP 8 0 2009

Parcus Medical, LLC c/o Mr. Barton Bracy VP Marketing and Product Development 839 South Neenah Avenue Sturgeon Bay, Wisconsin 54235

Re: K091094

Trade/Device Name: Parcus V-Lox™ PEEK CF Suture Anchor

Regulation Number: 21 CFR 888,3040

Regulation Name: Smooth or threaded metallic bone fixation fastener

Regulatory Class: Class II Product Code: HWC, MBI Dated: September 23, 2009 Received: September 30, 2009

Dear Mr. Bracy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Mark N. Melkerson

Director Division of Surgical, Orthopedic

and Restorative Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

	Device Nam	Device Name: _Parcus V-LoX <sup>™</sup> PEEK CF Suture Anchor						
	Indications	ndications for Use:						
	The Parcus V-LoX <sup>™</sup> PEEK CF Suture Anchors are indicated for attachment of soft tissue to bone. This product is intended for the following indications:							
	<u>Shoulder</u>	Repair, Biceps Ter		r Separation Repair, Ban hift or Capsulolabral Lesion Repair.	kart Lesion			
	<u>Knee</u>	Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Posterior Oblique Ligament Repair, Extra Capsular Reconstruction, Iliotibial Band Tenodesis, Patellar Ligament and Tendon Avulsion Repair.						
	Foot/Ankle	Lateral Stabilization, Medial Stabilization, Midfoot Reconstruction, Achilles Tendon Repair, Hallux Valgus Reconstruction, Metatarsal Ligament Repair.						
	<u>Elbow</u>	Tennis Elbow Repair, Biceps Tendon Reattachment.						
	<u>Hand/Wrist</u>	Scapholunate Liga Ligament Reconstr		n, Ulnar or Radial Collat	l Collateral			
		·		•	•			
				:	re P			
	Prescription	UseX	AND/OR	Over the Counter	Use			
	(Part 21 CFF	R 801 Subpart D)		(21 CFR 801 Sub	801 Subpart C)			
	(PLEASE DO	NOT WRITE BELOW	THIS LINE - CONTIN	NUE ON ANOTHER PAGE	IF NEEDED)			
ı Hı	2 60	1VACConcurrence of	CDRH. Office of Device	ce Evaluation (ODE)	maging a statement of the confidence of the parties			
ion S	ien-Off)	•	BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)  ence of CDRH, Office of Device Evaluation (ODE)					
n of	Surgical, Orth	opedic,		·				
or	ative Devices		Page 13 of 144					

510(k) Number K091094